@article{10.11648/j.cmr.20241302.12,
  author = {Li Huyu and Liu Dongdong and Liu Chao},
  title = {Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema
},
  journal = {Clinical Medicine Research},
  volume = {13},
  number = {2},
  pages = {23-28},
  doi = {10.11648/j.cmr.20241302.12},
  url = {https://doi.org/10.11648/j.cmr.20241302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20241302.12},
  abstract = {Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema

AU  - Li Huyu
AU  - Liu Dongdong
AU  - Liu Chao
Y1  - 2024/05/30
PY  - 2024
N1  - https://doi.org/10.11648/j.cmr.20241302.12
DO  - 10.11648/j.cmr.20241302.12
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 23
EP  - 28
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20241302.12
AB  - Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.

VL  - 13
IS  - 2
ER  - 

Copy | Download